Is BPC-157 legal now? Status after the Oct 28, 2026 HHS policy

Reader noteTreatment decisions belong with a licensed clinician who knows your history.

THE BOTTOM LINE

Since October 30, 2026, HHS says it will not take enforcement action against state-licensed 503A pharmacies, federal facilities and licensed physicians that compound BPC-157 under the conditions in its October 28 policy. So getting BPC-157 through a prescriber and a licensed compounding pharmacy now has a federal path. Buying a “research use only” vial to inject yourself does not. BPC-157 is still not FDA approved, the policy is interim and non-binding, and it remains banned in WADA-tested sport.

SIDE-BY-SIDE

What actually differs

FactorPrescription + licensed 503A pharmacyResearch-use-only vial

Covered by the Oct 28 policyYes, if every condition is metNo

Needs a prescriberYesNo, which is the problem

Ingredient sourceFDA-registered facility, certificate of analysisUnverified

FDA approvedNoNo

Allowed in WADA-tested sportNoNo

What “legal” means here

BPC-157 is not an approved drug, so nothing about it is “FDA approved.” What changed on October 28, 2026 is enforcement. HHS published a policy saying that, starting October 30, it does not intend to act against covered compounders that make BPC-157 and five other peptides (Epitalon, KPV, MOTS-c, Semax and TB-500) if they meet a list of conditions.

That is a meaningful change. Before it, BPC-157 sat on FDA's list of bulk substances with significant safety concerns, and compounders who used it risked enforcement. Now there is a defined lane: a licensed prescriber, a state-licensed 503A pharmacy, a verified ingredient and a single-ingredient product.

What is still not allowed

The policy does not cover research-chemical vendors, blends such as BPC-157 with TB-500, or routes it does not list. For BPC-157 the listed routes are subcutaneous, intramuscular, oral and topical. Oral products need documentation that the formula is adequately absorbed.

It also does not override state law or sport rules. BPC-157 has been named on the WADA Prohibited List since 2022 and is banned in and out of competition.

How long this lasts

The policy is interim. It runs while FDA works through rulemaking on the 503A bulks list, and HHS says it can revisit the policy if a safety or quality problem appears. Public comments are open through November 13, 2026. Treat the current setup as the rule today, not a permanent guarantee.

QUICK ANSWERS

Is BPC-157 legal in the US?

Since October 30, 2026, licensed 503A pharmacies and physicians can compound BPC-157 for patients with a prescription without federal enforcement, provided they meet the HHS policy conditions. It is still not FDA approved, and research-use-only products are not covered.

Is BPC-157 FDA approved?

No. Compounded drugs are not FDA approved, and the October 28 policy is enforcement discretion, not approval.

Can athletes use BPC-157?

Not in WADA-tested sport. BPC-157 is listed under S0 and is prohibited at all times.

PRIMARY & AUTHORITATIVE SOURCES

Check the underlying record

Federal Register: HHS enforcement discretion policy, 503A peptide compounding (public inspection)↗HHS policy appendix B (PDF)↗Frier Levitt: what the peptide policy covers, by route↗NCPA: FDA grants enforcement discretion to compounding six peptides↗AJMC: 5 things to know about the interim peptide compounding policy↗

Regulatory status and labeling can change. Sources were reviewed on the article update date; current prescribing information controls.

PROVIDER TO CHECK

Live Vital

A physician-supervised telehealth company offering compounded BPC-157 under the October 28 policy, with treatment decisions made by a licensed clinician. Run it through the seven questions on our BPC-157 review before you start.

Check BPC-157 eligibility at Live Vital →Televetted may earn a commission if you sign up through this link. Payment never changes the facts we report. This is not a rating under the Televetted Method.

Evidence reviewBPC-157 after the October 28 policy: what changed, what didn't, and how to check a provider How toHow to get BPC-157 through telehealth, and what a legitimate provider looks like ComparisonResearch-use-only vs. pharmacy-compounded BPC-157: why the label matters now Claim checkThe BPC-157 + TB-500 “Wolverine stack” is not covered by the new policy ComparisonOral vs. injectable BPC-157: which forms the policy covers, and what to ask

COMPARE THE CARE MODEL

Medication is only one part of the decision.

Use the 30-second filter to identify the costs, clinical safeguards and service terms worth checking before you enroll.

Find my starting point →